A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
Authors
Lin, Huapeng ; Li, Guanlin ; Delamarre, Adele ; Ahn, Sang Hoon ; Zhang, Xinrong ; Kim, Beom Kyung ; Liang, Lilian Yan ; Lee, Hye Won ; Wong, Grace Lai -Hung ; Yuen, Pong-Chi ; Chan, Henry Lik-Yuen ; Chan, Stephen Lam ; Wong, Vincent Wai-Sun ; de Ledinghen, Victor ; Kim, Seung Up ; Yip, Terry Cheuk-Fung
Citation
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.22(3) : 602-610, 2024-03
BACKGROUND & AIMS: The existing hepatocellular carcinoma (HCC) risk scores have modest accuracy, and most are specific to chronic hepatitis B infection. In this study, we developed and validated a liver stiffness-based machine learning algorithm (ML) for prediction and risk stratification of HCC in various chronic liver diseases (CLDs). METHODS: MLs were trained for prediction of HCC in 5155 adult patients with various CLDs in Korea and further tested in 2 prospective cohorts from Hong Kong (HK) (N = 2732) and Europe (N = 2384). Model performance was assessed according to Harrell's C -index and time -dependent receiver operating characteristic (ROC) curve. RESULTS: We developed the SMART-HCC score, a liver stiffness-based ML HCC risk score, with liver stiffness measurement ranked as the most important among 9 clinical features. The Harrell's Cindex of the SMART-HCC score in HK and Europe validation cohorts were 0.89 (95% confidence interval, 0.85-0.92) and 0.91 (95% confidence interval, 0.87-0.95), respectively. The area under ROC curves of the SMART-HCC score for HCC in 5 years was double dagger 0.89 in both validation cohorts. The performance of SMART-HCC score was significantly better than existing HCC risk scores including aMAP score, Toronto HCC risk index, and 7 hepatitis B-related risk scores. Using dual cutoffs of 0.043 and 0.080, the annual HCC incidence was 0.09%-0.11% for low -risk group and 2.54%-4.64% for high -risk group in the HK and Europe validation cohorts. CONCLUSIONS: The SMART-HCC score is a useful machine learning-based tool for clinicians to stratify HCC risk in patients with CLDs.